Regulation of glycogen synthase kinase-3 by thymosin beta-4 is associated with gastric cancer cell migration

Int J Cancer. 2012 Nov 1;131(9):2067-77. doi: 10.1002/ijc.27490. Epub 2012 Mar 28.

Abstract

Thymosin beta-4 (Tβ4), actin-sequestering protein, plays important roles in many cellular functions including cancer cell migrations. Glycogen synthase kinase (GSK) in Wnt signaling pathway is a key molecule to control intercellular interaction. Here, we investigated whether GSK-3 activity is regulated by Tβ4 and it is associated with Tβ4-mediated migration in gastric cancer cells. Various expression level of Tβ4 was observed in human gastric tumor tissues. Migration in gastric cancer cells, SNU638 and SNU668, was dependent on a relative expression level of Tβ4. Cell migration was higher in SNU668 with a higher expression level of Tβ4 than that in SNU638 with a lower Tβ4. Although the level of phosphorylated(p)-GSK-3α (inactive), β-catenin, E-cadherin and E-cadherin:β-catenin complex was relatively higher, p-GSK-3β (inactive) was lower in SNU638 compared to those in SNU668 cells. LiCl, GSK-3α/β inhibitor, reduced lung metastasis of B16F10 mouse melanoma cells and SNU668 cell migration. Small interference (si)RNA of GSK-3α increased SNU638 cell migration in accordance with the reduction of E-cadherin:β-catenin complex formation through a decrease in β-catenin and E-cadherin. Expression level of GSK-3α/β, β-catenin and E-cadherin in SNU668 and SNU638 was reversed by Tβ4-siRNA and by the treatment with acetylated-serine-aspartic acid-lysine-proline (SDKP) tetrapeptide of Tβ4, respectively. E-cadherin expression in SNU638 cells was decreased by β-catenin-siRNA. PD98059, MEK inhibitor, or U0126, ERK inhibitor, reduced SNU668 cell migration accompanying an increase in p-GSK-3α, β-catenin and E-cadherin. Taken together, data indicated that the expression of GSK-3α, β-catenin and E-cadherin could be negatively regulated by Tβ4-induced ERK phosphorylation. It suggests that Tβ4 could be a novel regulator to control Wnt signaling pathways.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Butadienes / pharmacology
  • Cadherins / biosynthesis*
  • Calcium-Calmodulin-Dependent Protein Kinases / antagonists & inhibitors
  • Cell Line, Tumor
  • Cell Movement / drug effects
  • Enzyme Inhibitors / pharmacology
  • Extracellular Signal-Regulated MAP Kinases / metabolism
  • Female
  • Flavonoids / pharmacology
  • Glycogen Synthase Kinase 3 / genetics
  • Glycogen Synthase Kinase 3 / metabolism*
  • Humans
  • Lithium Chloride / pharmacology
  • Lung Neoplasms / secondary
  • Melanoma, Experimental / metabolism
  • Melanoma, Experimental / secondary
  • Mice
  • Mice, Inbred C57BL
  • Nitriles / pharmacology
  • Peptides / pharmacology
  • Phosphorylation
  • RNA Interference
  • RNA, Small Interfering
  • Stomach Neoplasms / metabolism*
  • Stomach Neoplasms / pathology
  • Thymosin / genetics
  • Thymosin / metabolism*
  • Wnt Signaling Pathway
  • beta Catenin / biosynthesis*

Substances

  • Butadienes
  • Cadherins
  • Enzyme Inhibitors
  • Flavonoids
  • Nitriles
  • Peptides
  • RNA, Small Interfering
  • U 0126
  • beta Catenin
  • thymosin beta(4)
  • Thymosin
  • Calcium-Calmodulin-Dependent Protein Kinases
  • Extracellular Signal-Regulated MAP Kinases
  • Glycogen Synthase Kinase 3
  • Lithium Chloride
  • 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one